Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan 430060, PR China; Chongqing Academy of Chinese Materia Medica, Chongqing, 400065, PR China.
College of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan, 430065, PR China.
Carbohydr Polym. 2021 Feb 1;253:117218. doi: 10.1016/j.carbpol.2020.117218. Epub 2020 Oct 13.
This study was designed to explore the improvement of chitosan oligosaccharides (COS) on constipation through regulation of gut microbiota. Here, we proved that COS treatment profoundly boosted intestinal motility, restrained inflammatory responses, improved water-electrolyte metabolism and prevented gut barrier damage in constipated mice induced by loperamide. By 16S rDNA gene sequencing, the disbalanced gut microbiota was observed in constipated mice, while COS treatment statistically reversed the abundance changes of several intestinal bacteria at either phylum, family and genus levels, which partly led to the balance in production of intestinal metabolites including bile acids, short-chain fatty acids and tryptophan catabolites. In addition, COS failed to relieve the constipation in mice with intestinal flora depletion, confirming the essentiality of gut microbiota in COS-initiated prevention against constipation. In summary, COS can ameliorate the development of loperamide-induced constipation in mice by remodeling the structure of gut microbial community.
本研究旨在探讨壳寡糖（COS）通过调节肠道微生物群改善便秘的作用。在这里，我们证明了 COS 处理可显著促进肠道蠕动，抑制炎症反应，改善水-电解质代谢，防止洛哌丁胺诱导的便秘小鼠的肠道屏障损伤。通过 16S rDNA 基因测序，观察到便秘小鼠的肠道微生物群失衡，而 COS 处理在门、科和属水平上统计上逆转了几种肠道细菌的丰度变化，这部分导致了肠道代谢产物（包括胆汁酸、短链脂肪酸和色氨酸代谢物）的产生平衡。此外，COS 未能缓解肠道菌群耗竭小鼠的便秘，证实了肠道微生物群在 COS 预防便秘中的重要性。总之，COS 通过重塑肠道微生物群落的结构可以改善洛哌丁胺诱导的便秘小鼠的发展。
